Katherine E. Zarn

Katherine E. Zarn

Auto-generated profile, based on publicly available information

Katherine E. Zarn

Affiliation Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, United States of America

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Molecular Ecology Resources
Verified
Journal Article
Closed access
PDF file
TWTaylor M. Wilcox
Taylor M. Wilcox
KZKatherine E. Zarn
Katherine E. Zarn
MPMaxine Piggott
Maxine Piggott
MYMichael K. Young
Michael K. Young
KMKevin S. McKelvey
Kevin S. McKelvey
MSMichael K. Schwartz
Michael K. Schwartz

27 February 2019 in Wildlife Society Bulletin
Verified
Journal Article
Open access
PDF file
GRGretchen Roffler
Gretchen Roffler
JWJason N. Waite
Jason N. Waite
KPKristine L. Pilgrim
Kristine L. Pilgrim
KZKatherine E. Zarn
Katherine E. Zarn
MSMichael K. Schwartz
Michael K. Schwartz
Estimating population abundance of wolves ( Canis lupus ) in densely forested landscapes is challenging because reduced visibility lowers the success of methods such as aerial surveys and enumeration of group size using radiotelemetry. However, regular population estimates of wolves are necessary for population monitoring and sustainable management. We used noninvasive hair snaring and spatially explicit capture–recapture (SECR) to estimate wolf abundance on Prince of Wales Island (POW), Alaska, USA, during 2012–2015. We monitored 36–82 hair‐snare stations weekly for 9–11 weeks during autumn. The noninvasive study area covered 1,683 km 2 during 2012–2013 and was expanded to 3,281 km 2 during 2014–2015. We identified 57 individual wolves during the study period using DNA from hair follicles genotyped at 10 microsatellite loci. We used population density estimates using SECR (2013: 24.5 wolves/1,000 km 2 [95% CI = 14.4–41.9 wolves/1,000 km 2 ], 2014: 9.9 wolves/1,000 km 2 [95% CI = 5.5–17.7/1,000 km 2 ], 2015: 11.9 wolves/1,000 km 2 [95% CI = 7.7–18.5 wolves/1,000 km 2 ]) to predict the autumn population for the POW management unit (2013: 221.1 wolves [95% CI = 130–378]; 2014: 89.1 wolves [95% CI = 49.8–159.4]; 2015: 107.5 wolves [95% CI = 69–167]). We detected and redetected more wolves and increased the precision of the density estimate after increasing the hair sampling intensity and sampling area in 2014–2015. Our results demonstrate that estimating wolf abundance using noninvasive sampling and SECR was feasible and reliably applied producing a statistically robust population estimate for monitoring wolf populations in densely forested areas. These methods have promise for application to widely ranging carnivores at population‐level scales and may be especially useful when regular density estimates are necessary for management and conservation. © 2019 The Wildlife Society.

14 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KZKatherine E. Zarn
Katherine E. Zarn
SJSierra A. Jaramillo
Sierra A. Jaramillo
AZAnthony R. Zapata
Anthony R. Zapata
NSNathan E. Stone
Nathan E. Stone
AJAshley N. Jones
Ashley N. Jones
CFChristopher T. French
Christopher T. French
We recently published a preliminary assessment of the activity of a poly (ADP-ribose) polymerase (PARP) inhibitor, stenoparib, also known as 2X-121, which inhibits viral replication by affecting pathways of the host. Here we show that stenoparib effectively inhibits a SARS-CoV-2 wild type (BavPat1/2020) strain and four additional variant strains; alpha (B.1.1.7), beta (B.1.351), delta (B.1.617.2) and gamma (P.1) in vitro, with 50% effective concentration (EC50) estimates of 4.1 μM, 8.5 μM, 24.1 μM, 8.2 μM and 13.6 μM, respectively. A separate experiment focusing on a combination of 10 μM stenoparib and 0.5 μM remdesivir, an antiviral drug, resulted in over 80% inhibition of the alpha variant, which is substantially greater than the effect achieved with either drug alone, suggesting at least additive effects from combining the different mechanisms of activity of stenoparib and remdesivir.